According to the Complaint, Ampio Pharmaceuticals, Inc. ("Ampio") is a biopharmaceutical company which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States.

The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

On September 27, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on December 10. Defendants filed a Motion to Dismiss the amended Complaint on February 10, 2020. On June 19, the Court issued an Order granting Defendants' Motion to Dismiss. The case was dismissed with prejudice.